首页 > 最新文献

Nephrology最新文献

英文 中文
Identification of circulating microbial DNA and its association with kidney function in patients with diabetic kidney disease. 鉴定糖尿病肾病患者的循环微生物 DNA 及其与肾功能的关系。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-23 DOI: 10.1111/nep.14408
Hoang Thuy Linh, Megumi Oshima, Keisuke Sako, Masahiro Konishi, Daiki Hayashi, Hajime Sanada, Takahiro Yuasa, Akihiko Koshino, Keisuke Horikoshi, Taichiro Minami, Shunsuke Tsuge, Akira Tamai, Shiori Nakagawa, Ryo Nishioka, Takeshi Zoshima, Kiyoaki Ito, Ichiro Mizushima, Tadashi Toyama, Norihiko Sakai, Shinji Kitajima, Miho Shimizu, Takashi Wada, Yasunori Iwata

Aim: Recently, substantial studies have been accumulated to indicate the important role of gut microbiota in diabetic kidney disease (DKD). The abnormal change of bacterial-derived products could imply specific injuries or play beneficial or harmful roles in DKD progression. In this study, we examined the presence and contribution of the Klebsiella oxytoca gene in the circulation of patients with DKD.

Method: We enrolled a total of 16 healthy participants, 17 patients with DKD, 5 patients with DKD requiring haemodialysis (HD), and 7 patients with CKD without diabetes. Bacterial-derived DNA (16S rDNA and a specific K. oxytoca gene) in the blood was detected using droplet digital PCR, then investigated the relationship with clinical characteristics.

Results: We identified an increase in K. oxytoca genes in the blood of DKD patients. Interestingly, blood K. oxytoca copies and K. oxytoca/ 16S DNA ratio correlated with higher blood creatinine and BUN levels together with lower eGFR in DKD patients. K. oxytoca levels were also associated with higher neutrophil percentage, lower lymphocyte frequency, and increased neutrophil-to-lymphocyte ratio.

Conclusion: Collectively, the presence of the K. oxytoca gene in the circulation could serve as a biomarker reflecting reduced renal function in DKD patients.

目的:最近,大量研究表明,肠道微生物群在糖尿病肾病(DKD)中发挥着重要作用。细菌衍生产物的异常变化可能意味着特定的损伤,或在 DKD 的发展过程中发挥有益或有害的作用。在这项研究中,我们检测了 DKD 患者血液循环中氧合克雷伯氏菌基因的存在和贡献:我们共招募了 16 名健康参与者、17 名 DKD 患者、5 名需要血液透析(HD)的 DKD 患者和 7 名无糖尿病的 CKD 患者。使用液滴数字 PCR 检测血液中的细菌衍生 DNA(16S rDNA 和一个特异的 K. oxytoca 基因),然后研究其与临床特征的关系:结果:我们在 DKD 患者的血液中发现了土佐卡氏菌基因的增加。有趣的是,在 DKD 患者中,血液中 K. oxytoca 的拷贝数和 K. oxytoca/ 16S DNA 比值与较高的血肌酐和尿素氮水平以及较低的 eGFR 相关。K. oxytoca水平还与中性粒细胞百分比升高、淋巴细胞频率降低以及中性粒细胞与淋巴细胞比值升高有关:总而言之,血液循环中存在的 K. oxytoca 基因可作为一种生物标志物,反映 DKD 患者肾功能的减退。
{"title":"Identification of circulating microbial DNA and its association with kidney function in patients with diabetic kidney disease.","authors":"Hoang Thuy Linh, Megumi Oshima, Keisuke Sako, Masahiro Konishi, Daiki Hayashi, Hajime Sanada, Takahiro Yuasa, Akihiko Koshino, Keisuke Horikoshi, Taichiro Minami, Shunsuke Tsuge, Akira Tamai, Shiori Nakagawa, Ryo Nishioka, Takeshi Zoshima, Kiyoaki Ito, Ichiro Mizushima, Tadashi Toyama, Norihiko Sakai, Shinji Kitajima, Miho Shimizu, Takashi Wada, Yasunori Iwata","doi":"10.1111/nep.14408","DOIUrl":"10.1111/nep.14408","url":null,"abstract":"<p><strong>Aim: </strong>Recently, substantial studies have been accumulated to indicate the important role of gut microbiota in diabetic kidney disease (DKD). The abnormal change of bacterial-derived products could imply specific injuries or play beneficial or harmful roles in DKD progression. In this study, we examined the presence and contribution of the Klebsiella oxytoca gene in the circulation of patients with DKD.</p><p><strong>Method: </strong>We enrolled a total of 16 healthy participants, 17 patients with DKD, 5 patients with DKD requiring haemodialysis (HD), and 7 patients with CKD without diabetes. Bacterial-derived DNA (16S rDNA and a specific K. oxytoca gene) in the blood was detected using droplet digital PCR, then investigated the relationship with clinical characteristics.</p><p><strong>Results: </strong>We identified an increase in K. oxytoca genes in the blood of DKD patients. Interestingly, blood K. oxytoca copies and K. oxytoca/ 16S DNA ratio correlated with higher blood creatinine and BUN levels together with lower eGFR in DKD patients. K. oxytoca levels were also associated with higher neutrophil percentage, lower lymphocyte frequency, and increased neutrophil-to-lymphocyte ratio.</p><p><strong>Conclusion: </strong>Collectively, the presence of the K. oxytoca gene in the circulation could serve as a biomarker reflecting reduced renal function in DKD patients.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"909-916"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of statin use with in-hospital mortality in patients with acute kidney injury during hospitalization: A retrospective analysis. 急性肾损伤患者住院期间使用他汀类药物与院内死亡率的关系:回顾性分析
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1111/nep.14411
Xi-Zi Zheng, Yi-Dan Zhu, Ling-Er Tang, Qing-Qing Zhou, Ling-Yi Xu, Da-Min Xu, You-Lu Zhao, Ji-Cheng Lv, Li Yang

Aim: Acute kidney injury (AKI) is a severe condition in hospitalized patients and carries high mortality. The influence of statin use on the outcomes of AKI patients remains inconsistent. We aimed to discover the association between statin use and in-hospital mortality.

Methods: This retrospective study screened all adult admissions in Peking University First Hospital between 1 January 2018 and 31 December 2020, and patients with AKI during hospitalization were included. Exposure was defined as any statin prescription prior to AKI onset. Patients were followed up until death or discharge. The primary outcome was in-hospital all-cause mortality; secondary outcomes included cardiovascular- and sepsis-related mortality, elevated transaminases, rhabdomyolysis and kidney nonrecovery at discharge.

Results: A total of 2034 AKI patients were included. 551 (27%) patients were statin users. During a median of 10 days of follow-up, we documented 283 (14%) in-hospital deaths. Compared with statin nonusers, statin users experienced a significantly lower risk in in-hospital all-cause mortality (adjust hazard ratio [aHR], 0.54; 95% CI, 0.35-0.84) and cardiovascular-related mortality (aHR, 0.48; 95% CI, 0.24-0.97) after covariate adjustment. The survival benefit of statin use was consistent across subgroups, that is, age, sex, initial AKI stage and major surgery (all P for heterogeneity >.05). For sepsis-related mortality, elevated transaminases, rhabdomyolysis and kidney nonrecovery, the association was no longer significant in the fully adjusted model. For any type of statins, a statistically significant association was only observed in atorvastatin (aHR, 0.49; 95% CI, 0.30-0.81).

Conclusions: Statin use may improve survival, and atorvastatin may be preferred in patients with AKI.

目的:急性肾损伤(AKI)是住院患者的一种严重疾病,死亡率很高。他汀类药物的使用对 AKI 患者预后的影响仍不一致。我们旨在发现他汀类药物的使用与院内死亡率之间的关系:这项回顾性研究筛查了北京大学第一医院 2018 年 1 月 1 日至 2020 年 12 月 31 日期间的所有成人住院患者,并纳入了住院期间发生 AKI 的患者。他汀类药物暴露定义为 AKI 发病前的任何他汀类药物处方。对患者进行随访,直至死亡或出院。主要结果是院内全因死亡率;次要结果包括心血管和脓毒症相关死亡率、转氨酶升高、横纹肌溶解和出院时肾脏未恢复:共纳入 2034 名 AKI 患者。551名(27%)患者使用他汀类药物。在中位 10 天的随访期间,我们记录了 283 例(14%)院内死亡病例。与他汀类药物非使用者相比,他汀类药物使用者的院内全因死亡率(调整危险比 [aHR],0.54;95% CI,0.35-0.84)和心血管相关死亡率(aHR,0.48;95% CI,0.24-0.97)在协变量调整后明显降低。使用他汀类药物的生存获益在不同亚组,即年龄、性别、初始 AKI 分期和主要手术中是一致的(异质性 P >.05)。对于脓毒症相关死亡率、转氨酶升高、横纹肌溶解症和肾功能未恢复,在完全调整模型中相关性不再显著。对于任何类型的他汀类药物,只有阿托伐他汀的相关性具有统计学意义(aHR,0.49;95% CI,0.30-0.81):结论:使用他汀类药物可提高生存率,AKI患者可首选阿托伐他汀。
{"title":"The association of statin use with in-hospital mortality in patients with acute kidney injury during hospitalization: A retrospective analysis.","authors":"Xi-Zi Zheng, Yi-Dan Zhu, Ling-Er Tang, Qing-Qing Zhou, Ling-Yi Xu, Da-Min Xu, You-Lu Zhao, Ji-Cheng Lv, Li Yang","doi":"10.1111/nep.14411","DOIUrl":"10.1111/nep.14411","url":null,"abstract":"<p><strong>Aim: </strong>Acute kidney injury (AKI) is a severe condition in hospitalized patients and carries high mortality. The influence of statin use on the outcomes of AKI patients remains inconsistent. We aimed to discover the association between statin use and in-hospital mortality.</p><p><strong>Methods: </strong>This retrospective study screened all adult admissions in Peking University First Hospital between 1 January 2018 and 31 December 2020, and patients with AKI during hospitalization were included. Exposure was defined as any statin prescription prior to AKI onset. Patients were followed up until death or discharge. The primary outcome was in-hospital all-cause mortality; secondary outcomes included cardiovascular- and sepsis-related mortality, elevated transaminases, rhabdomyolysis and kidney nonrecovery at discharge.</p><p><strong>Results: </strong>A total of 2034 AKI patients were included. 551 (27%) patients were statin users. During a median of 10 days of follow-up, we documented 283 (14%) in-hospital deaths. Compared with statin nonusers, statin users experienced a significantly lower risk in in-hospital all-cause mortality (adjust hazard ratio [aHR], 0.54; 95% CI, 0.35-0.84) and cardiovascular-related mortality (aHR, 0.48; 95% CI, 0.24-0.97) after covariate adjustment. The survival benefit of statin use was consistent across subgroups, that is, age, sex, initial AKI stage and major surgery (all P for heterogeneity >.05). For sepsis-related mortality, elevated transaminases, rhabdomyolysis and kidney nonrecovery, the association was no longer significant in the fully adjusted model. For any type of statins, a statistically significant association was only observed in atorvastatin (aHR, 0.49; 95% CI, 0.30-0.81).</p><p><strong>Conclusions: </strong>Statin use may improve survival, and atorvastatin may be preferred in patients with AKI.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"849-857"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An increasing trend of overweight and obesity in the Japanese incident end-stage kidney disease population. 日本终末期肾病患者超重和肥胖呈上升趋势。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-27 DOI: 10.1111/nep.14410
Minako Wakasugi, Shin Goto

Aim: The global prevalence of overweight/obesity has been rising, and this trend is apparent in US and European incident end-stage kidney disease (ESKD) populations. We aimed to examine temporal trends in the prevalence of overweight/obesity and underweight among adult incident ESKD patients in Japan by year of dialysis initiation between 2006 and 2019 in comparison with those observed in the Japanese adult population during the same period.

Methods: Using data from the Japanese Society of Dialysis Therapy Renal Data Registry and the National Health and Nutrition Survey, the sex-specific prevalence of overweight/obesity and that of underweight (BMI ≥ 25 kg/m2 and <18.5 kg/m2, respectively) were calculated, adjusted for age according to the 2019 Population Census via the direct method. Average annual percentage changes (AAPCs) and corresponding 95% confidence intervals (CIs) were calculated to examine trends.

Results: From 2006 to 2019, the age-adjusted prevalence of overweight/obesity in the incident ESKD population increased for males (AAPC 3.36 [95% CI, 2.70 to 4.09]) and females (AAPC 2.86 [95% CI, 1.65 to 4.19]). The age-adjusted prevalence of overweight/obesity in the general population increased for males (AAPC 0.87 [95% CI, 0.26 to 1.42]) but not for females (AAPC 0.01 [95% CI, -0.55 to 0.57]). The age-adjusted prevalence of underweight in the incident ESKD population significantly decreased but was higher than that in the general population for both sexes.

Conclusion: An increasing trend of overweight/obesity was observed in the incident ESKD population in Japan. There is a pressing need to address both underweight and overweight/obesity in the incident ESKD population.

目的:全球超重/肥胖患病率一直在上升,这一趋势在美国和欧洲的终末期肾病(ESKD)发病人群中也很明显。我们的目的是研究 2006 年至 2019 年间日本成年终末期肾病(ESKD)患者中按开始透析年份划分的超重/肥胖和体重不足患病率的时间趋势,并与同期日本成年人口中观察到的趋势进行比较:利用日本透析治疗学会肾脏数据登记处和全国健康与营养调查的数据,计算了超重/肥胖和体重不足(BMI 分别≥ 25 kg/m2 和 2)的性别特异性患病率,并根据 2019 年人口普查通过直接法对年龄进行了调整。计算年均百分比变化(AAPCs)和相应的95%置信区间(CIs),以研究趋势:从2006年到2019年,在ESKD事件人群中,男性(AAPC为3.36 [95% CI,2.70至4.09])和女性(AAPC为2.86 [95% CI,1.65至4.19])经年龄调整的超重/肥胖患病率均有所上升。经年龄调整后,男性超重/肥胖症在普通人群中的流行率有所上升(AAPC 0.87 [95% CI, 0.26 to 1.42]),而女性则没有上升(AAPC 0.01 [95% CI, -0.55 to 0.57])。在ESKD发病人群中,经年龄调整后的体重不足发生率显著下降,但男女均高于普通人群:结论:在日本的 ESKD 患者中,超重/肥胖率呈上升趋势。迫切需要解决ESKD发病人群中体重不足和超重/肥胖的问题。
{"title":"An increasing trend of overweight and obesity in the Japanese incident end-stage kidney disease population.","authors":"Minako Wakasugi, Shin Goto","doi":"10.1111/nep.14410","DOIUrl":"10.1111/nep.14410","url":null,"abstract":"<p><strong>Aim: </strong>The global prevalence of overweight/obesity has been rising, and this trend is apparent in US and European incident end-stage kidney disease (ESKD) populations. We aimed to examine temporal trends in the prevalence of overweight/obesity and underweight among adult incident ESKD patients in Japan by year of dialysis initiation between 2006 and 2019 in comparison with those observed in the Japanese adult population during the same period.</p><p><strong>Methods: </strong>Using data from the Japanese Society of Dialysis Therapy Renal Data Registry and the National Health and Nutrition Survey, the sex-specific prevalence of overweight/obesity and that of underweight (BMI ≥ 25 kg/m<sup>2</sup> and <18.5 kg/m<sup>2</sup>, respectively) were calculated, adjusted for age according to the 2019 Population Census via the direct method. Average annual percentage changes (AAPCs) and corresponding 95% confidence intervals (CIs) were calculated to examine trends.</p><p><strong>Results: </strong>From 2006 to 2019, the age-adjusted prevalence of overweight/obesity in the incident ESKD population increased for males (AAPC 3.36 [95% CI, 2.70 to 4.09]) and females (AAPC 2.86 [95% CI, 1.65 to 4.19]). The age-adjusted prevalence of overweight/obesity in the general population increased for males (AAPC 0.87 [95% CI, 0.26 to 1.42]) but not for females (AAPC 0.01 [95% CI, -0.55 to 0.57]). The age-adjusted prevalence of underweight in the incident ESKD population significantly decreased but was higher than that in the general population for both sexes.</p><p><strong>Conclusion: </strong>An increasing trend of overweight/obesity was observed in the incident ESKD population in Japan. There is a pressing need to address both underweight and overweight/obesity in the incident ESKD population.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"884-894"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renin-angiotensin blockade ameliorates the progression of glomerular injury in podocyte-specific Ctcf knockout mice. 肾素-血管紧张素阻断剂可改善荚膜特异性 Ctcf 基因敲除小鼠肾小球损伤的进展。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-30 DOI: 10.1111/nep.14400
Keisuke Fujioka, Takashi Nagai, Tomoki Hattori, Shoji Kagami, Koji Yasutomo, Niels Galjart, Teruyoshi Hirayama, Hiroshi Kawachi, Maki Urushihara

Aim: Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin-angiotensin system (RAS). CCCTC-binding factor (CTCF) is a DNA-binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.

Methods: Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte-specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte-specific Ctcf knockout mice.

Results: Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte-specific Ctcf knockout mice. Both real-time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte-specific Ctcf knockout mice were significantly increased.

Conclusion: These results suggest that RAS is involved in the development of glomerulopathy in podocyte-specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte-specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis.

目的:多项研究表明,蛋白尿和肾组织损伤的进展与肾内肾素-血管紧张素系统(RAS)的激活有关。CCCTC 结合因子(CTCF)是一种 DNA 结合因子,在基因表达调控中发挥着重要作用。本研究旨在探讨 CTCF 缺乏对荚膜细胞表型的影响:方法:给荚膜特异性 Ctcf 基因敲除小鼠注射血管紧张素 II 1 型受体阻断剂(ARB),并进行组织学和生化分析。我们还研究了用磁珠从荚膜特异性 Ctcf 基因敲除小鼠的肾小球中分离出的荚膜细胞培养物在血管紧张素 II 刺激或无血管紧张素 II 刺激时荚膜蛋白表达的变化:结果:从荚膜细胞中删除 Ctcf 的小鼠出现肾小球病变,小鼠出现严重的进行性蛋白尿,肾功能受损。此外,ARBs 可抑制荚膜特异性 Ctcf 基因敲除小鼠肾小球病的发展。实时聚合酶链反应和免疫印迹均显示,在血管紧张素 II 刺激下的细胞培养物中,荚膜素的表达量减少。此外,从荚膜特异性 Ctcf 基因敲除小鼠体内分离的荚膜细胞培养物中,RAS 成分基因表达明显增加:这些结果表明,RAS 参与了荚膜特异性 Ctcf 基因敲除小鼠肾小球病变的发生。阐明荚膜特异性 Ctcf 基因敲除小鼠的病理生理学可为了解荚膜损伤与慢性肾小球肾炎之间的关系提供新的视角。
{"title":"Renin-angiotensin blockade ameliorates the progression of glomerular injury in podocyte-specific Ctcf knockout mice.","authors":"Keisuke Fujioka, Takashi Nagai, Tomoki Hattori, Shoji Kagami, Koji Yasutomo, Niels Galjart, Teruyoshi Hirayama, Hiroshi Kawachi, Maki Urushihara","doi":"10.1111/nep.14400","DOIUrl":"10.1111/nep.14400","url":null,"abstract":"<p><strong>Aim: </strong>Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin-angiotensin system (RAS). CCCTC-binding factor (CTCF) is a DNA-binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.</p><p><strong>Methods: </strong>Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte-specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte-specific Ctcf knockout mice.</p><p><strong>Results: </strong>Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte-specific Ctcf knockout mice. Both real-time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte-specific Ctcf knockout mice were significantly increased.</p><p><strong>Conclusion: </strong>These results suggest that RAS is involved in the development of glomerulopathy in podocyte-specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte-specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"815-824"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining the genetic diagnostic puzzle: A case report on a Chinese ARPKD patient with a reciprocal balanced translocation and c.2507 T > C (p.V836A) in PKHD1. 完善基因诊断难题:一例中国ARPKD患者的病例报告,该患者患有PKHD1互补平衡易位和c.2507 T > C (p.V836A)。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-13 DOI: 10.1111/nep.14401
Xiaoyu Liu, Wenchao Sheng, Nan Liu, Wenxuan Fan, Shuyue Zhang, Yuanyuan Sun, Yingzi Cai, Dong Li, Jianbo Shu, Chunquan Cai

Introduction: Autosomal recessive polycystic kidney disease (ARPKD) ranks among the most severe chronic kidney diseases (CKD). Its primary cause is variants in the Polycystic Kidney and Hepatic Disease 1 gene (PKHD1). The clinical spectrum of ARPKD varies widely, ranging from mild late-onset symptoms to severe perinatal mortality. However, achieving an early genetic diagnosis in ARPKD patients before clinical symptoms appear proves challenging.

Case presentation: This case is a 4-year-old boy who experienced a convulsion characterized by a generalized tonic attack lasting approximately 3-5 minutes and later sought treatment to our hospital. However, routine abdominal ultrasound examination accidentally detected that he had diffuse liver lesions, splenomegaly, and bilateral renal enlargement with renal pelvis dilation. Given the uncertainty regarding the underlying cause of the patient's structural abnormalities and convulsions, karyotyping, whole exome sequencing (WES), structural variant analysis (SV analysis) of whole genome sequencing (WGS) were recommended. The result of SV analysis revealed that he has an RBT impacting PKHD1 and the precise location of breakpoints was confirmed through Long-Range Polymerase Chain Reaction (LR-PCR). However, WES did not screen out pathogenic variants initially, the WES data was reviewed subsequently based on SV analysis results.

Conclusion: We identified an infrequent variant combination, c.2507T>C (p.V836A) in PKHD1 and an RBT with broken PKHD1, which extends the genetic spectrum of ARPKD, and provide a basis for further genetic counselling to the family.

导言:常染色体隐性遗传多囊肾病(ARPKD)是最严重的慢性肾脏疾病(CKD)之一。其主要病因是多囊肾和肝病 1 基因(PKHD1)的变异。ARPKD 的临床表现差异很大,既有轻微的晚发症状,也有严重的围产期死亡。然而,在临床症状出现之前对 ARPKD 患者进行早期基因诊断具有挑战性:本病例是一名 4 岁男童,他经历了一次持续约 3-5 分钟的全身强直性抽搐,随后到我院就诊。然而,常规腹部超声检查意外发现他有弥漫性肝脏病变、脾脏肿大、双侧肾脏肿大伴肾盂扩张。鉴于患者结构异常和抽搐的潜在病因不明确,建议进行核型分析、全外显子组测序(WES)、全基因组测序(WGS)的结构变异分析(SV分析)。SV 分析结果显示,他患有影响 PKHD1 的 RBT,并通过长程聚合酶链反应(LR-PCR)确认了断点的精确位置。然而,WES 最初并未筛查出致病变异,后来根据 SV 分析结果对 WES 数据进行了复查:我们发现了一种不常见的变异组合,即 PKHD1 中的 c.2507T>C (p.V836A) 和带有 PKHD1 断裂的 RBT,这扩展了 ARPKD 的遗传谱,并为该家族的进一步遗传咨询提供了依据。
{"title":"Refining the genetic diagnostic puzzle: A case report on a Chinese ARPKD patient with a reciprocal balanced translocation and c.2507 T > C (p.V836A) in PKHD1.","authors":"Xiaoyu Liu, Wenchao Sheng, Nan Liu, Wenxuan Fan, Shuyue Zhang, Yuanyuan Sun, Yingzi Cai, Dong Li, Jianbo Shu, Chunquan Cai","doi":"10.1111/nep.14401","DOIUrl":"10.1111/nep.14401","url":null,"abstract":"<p><strong>Introduction: </strong>Autosomal recessive polycystic kidney disease (ARPKD) ranks among the most severe chronic kidney diseases (CKD). Its primary cause is variants in the Polycystic Kidney and Hepatic Disease 1 gene (PKHD1). The clinical spectrum of ARPKD varies widely, ranging from mild late-onset symptoms to severe perinatal mortality. However, achieving an early genetic diagnosis in ARPKD patients before clinical symptoms appear proves challenging.</p><p><strong>Case presentation: </strong>This case is a 4-year-old boy who experienced a convulsion characterized by a generalized tonic attack lasting approximately 3-5 minutes and later sought treatment to our hospital. However, routine abdominal ultrasound examination accidentally detected that he had diffuse liver lesions, splenomegaly, and bilateral renal enlargement with renal pelvis dilation. Given the uncertainty regarding the underlying cause of the patient's structural abnormalities and convulsions, karyotyping, whole exome sequencing (WES), structural variant analysis (SV analysis) of whole genome sequencing (WGS) were recommended. The result of SV analysis revealed that he has an RBT impacting PKHD1 and the precise location of breakpoints was confirmed through Long-Range Polymerase Chain Reaction (LR-PCR). However, WES did not screen out pathogenic variants initially, the WES data was reviewed subsequently based on SV analysis results.</p><p><strong>Conclusion: </strong>We identified an infrequent variant combination, c.2507T>C (p.V836A) in PKHD1 and an RBT with broken PKHD1, which extends the genetic spectrum of ARPKD, and provide a basis for further genetic counselling to the family.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"990-995"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An unusual case of Herbaspirillum huttiense bacteraemia in a haemodialysis patient. 血液透析患者中的一例罕见草履虫菌血症。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-04 DOI: 10.1111/nep.14385
Andrew M Fordyce, Frederiek Heenan-Vos, Tracey L Putt, Sine Donnellan, John W B Schollum, Robert J Walker

Herbaspirillum spp. is a common environmental bacterium usually found in soil, plant roots, and water. It is rarely associated with infection in immunocompromised patients, and rarely reported infections in immunocompetent patients. We report the first case of a Herbaspirillum huttiense bacteraemia in a non-neutropenic home haemodialysis patient. A 57-year-old male presented to our hospital with a 3-day history of malaise, fevers, rigours, and anorexia following dialysis through his central line. On examination, he was pyrexic (temperature 38.7°C) with splinter haemorrhages noted, but no other signs of infection were present. Blood cultures revealed a polymicrobial infection, with Serratia liquefaciens and Corynebacterium jeikeium isolated from the central line and Herbaspirillum sp. was isolated from both the central line and a peripheral culture. A later peripheral blood culture following central line removal isolated Herbaspirillum huttiense. Regular biological testing of his home water supply and dialysate detected no colony forming units of non-fermenting gram-negative bacilli. He was initially treated with ceftriaxone and vancomycin initially, followed by ertapenem and vancomycin. Intravenous antibiotics were ceased following 5 days after central line removal and he made an uneventful recovery.

Herbaspirillum spp.是一种常见的环境细菌,通常存在于土壤、植物根部和水中。它很少感染免疫力低下的患者,也很少报告感染免疫力正常的患者。我们报告了首例在非中性粒细胞减少的家庭血液透析患者中发生的赫伯斯比雷菌(Herbaspirillum huttiense)菌血症。一名 57 岁的男性患者在通过中心管路进行透析后,出现了 3 天的乏力、发热、全身僵硬和厌食症状,随后到我院就诊。经检查,他全身发热(体温 38.7°C)并伴有出血点,但没有其他感染迹象。血液培养显示存在多微生物感染,从中心管路中分离出液化沙雷氏菌和鸡冠状杆菌,从中心管路和外周血培养中分离出草吸虫。在移除中心静脉管后进行的外周血培养中分离出了胡提氏吸虫。对他家的供水和透析液进行的定期生物检测没有检测到非发酵革兰氏阴性杆菌的菌落形成单位。他最初接受了头孢曲松和万古霉素治疗,随后又接受了厄他培南和万古霉素治疗。拔除中心静脉置管 5 天后,他停止了静脉注射抗生素,并顺利康复。
{"title":"An unusual case of Herbaspirillum huttiense bacteraemia in a haemodialysis patient.","authors":"Andrew M Fordyce, Frederiek Heenan-Vos, Tracey L Putt, Sine Donnellan, John W B Schollum, Robert J Walker","doi":"10.1111/nep.14385","DOIUrl":"10.1111/nep.14385","url":null,"abstract":"<p><p>Herbaspirillum spp. is a common environmental bacterium usually found in soil, plant roots, and water. It is rarely associated with infection in immunocompromised patients, and rarely reported infections in immunocompetent patients. We report the first case of a Herbaspirillum huttiense bacteraemia in a non-neutropenic home haemodialysis patient. A 57-year-old male presented to our hospital with a 3-day history of malaise, fevers, rigours, and anorexia following dialysis through his central line. On examination, he was pyrexic (temperature 38.7°C) with splinter haemorrhages noted, but no other signs of infection were present. Blood cultures revealed a polymicrobial infection, with Serratia liquefaciens and Corynebacterium jeikeium isolated from the central line and Herbaspirillum sp. was isolated from both the central line and a peripheral culture. A later peripheral blood culture following central line removal isolated Herbaspirillum huttiense. Regular biological testing of his home water supply and dialysate detected no colony forming units of non-fermenting gram-negative bacilli. He was initially treated with ceftriaxone and vancomycin initially, followed by ertapenem and vancomycin. Intravenous antibiotics were ceased following 5 days after central line removal and he made an uneventful recovery.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"960-963"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of single centre kidney-exchange transplantation to increase living donor pool in India: A cohort study involving non-anonymous allocation. 单中心肾脏交换移植对增加印度活体供体库的影响:一项涉及非匿名分配的队列研究。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-08 DOI: 10.1111/nep.14380
Vivek B Kute, Himanshu V Patel, Subho Banerjee, Divyesh P Engineer, Ruchir B Dave, Nauka Shah, Sanshriti Chauhan, Harishankar Meshram, Priyash Tambi, Akash Shah, Khushboo Saxena, Manish Balwani, Vishal Parmar, Shivam Shah, Ved Prakash, Sudeep Patel, Dev Patel, Sudeep Desai, Jamal Rizvi, Harsh Patel, Beena Parikh, Kamal Kanodia, Shruti Gandhi, Michael A Rees, Alvin E Roth, Pranjal Modi

Aim: In India, 85% of organ donations are from living donors and 15% are from deceased donors. One-third of living donors were rejected because of ABO or HLA incompatibility. Kidney exchange transplantation (KET) is a cost-effective and legal strategy to increase living donor kidney transplantation (LDKT) by 25%-35%.

Methods: We report our experience with 539 KET cases and the evolution of a single-centre program to increase the use of LDKT.

Results: Between January 2000 and 13 March, 2024, 1382 deceased donor kidney transplantations and 5346 LDKT were performed at our centre, including 10% (n = 539) from KET. Of the 539 KET, 80.9% (n = 436) were ABO incompatible pairs, 11.1% (n = 60) were compatible pairs, and 8% (n = 43) were sensitized pairs. There were 75% 2-way (n = 2 × 202 = 404), 16.2% 3-way (n = 3 × 29 = 87), 3% 4-way (n = 4 × 4 = 16), 1.8% 5-way (n = 5 × 2 = 10), 2.2% 6-way (n = 6 × 2 = 12), and 1.8% 10-way KET (n = 10 × 1 = 10). Of the recipients 81.2% (n = 438) were male and 18.8% (n = 101) were female, while of the donors, 78.5% (n = 423) were female and 21.5% (n = 116) were male. All donors were near relatives; wives (54%, n = 291) and mothers (20%, n = 108) were the most common donors. At a median follow-up of 8.2 years, patient survival, death censored graft survival, acute rejection, and median serum creatinine levels of functioning grafts were 81.63% (n = 440), 91% (n = 494), 9.8% (n = 53) and 1.3 mg/dL respectively. We credited the success to maintaining a registry of incompatible pairs, high-volume LDKT programs, non-anonymous allocation and teamwork.

Conclusion: This is the largest single-centre KET program in Asia. We report the challenges and solutions to replicate our success in other KET programs.

目的:在印度,85% 的器官捐献者是活体捐献者,15% 是已故捐献者。三分之一的活体捐献者因 ABO 或 HLA 不相容而被拒绝。肾脏交换移植(KET)是一种成本效益高且合法的策略,可将活体肾脏移植(LDKT)率提高25%-35%:方法:我们报告了 539 例 KET 的经验,以及单中心计划提高 LDKT 使用率的演变过程:结果:2000年1月至2024年3月13日期间,我们中心共进行了1382例死体肾移植和5346例LDKT,其中10%(n = 539)来自KET。在 539 例 KET 中,80.9%(n = 436)为 ABO 不相容配对,11.1%(n = 60)为相容配对,8%(n = 43)为致敏配对。其中,75%为2对(n = 2 × 202 = 404),16.2%为3对(n = 3 × 29 = 87),3%为4对(n = 4 × 4 = 16),1.8%为5对(n = 5 × 2 = 10),2.2%为6对(n = 6 × 2 = 12),1.8%为10对KET(n = 10 × 1 = 10)。在受者中,81.2%(n = 438)为男性,18.8%(n = 101)为女性,而在捐献者中,78.5%(n = 423)为女性,21.5%(n = 116)为男性。所有捐献者都是近亲;妻子(54%,n = 291)和母亲(20%,n = 108)是最常见的捐献者。中位随访时间为 8.2 年,患者存活率、死亡剔除移植物存活率、急性排斥反应和功能正常移植物的中位血清肌酐水平分别为 81.63%(n = 440)、91%(n = 494)、9.8%(n = 53)和 1.3 mg/dL。我们将这一成功归功于不相容配对登记、高容量 LDKT 项目、非匿名分配和团队合作:这是亚洲最大的单中心 KET 项目。我们报告了在其他 KET 项目中复制我们的成功所面临的挑战和解决方案。
{"title":"Impact of single centre kidney-exchange transplantation to increase living donor pool in India: A cohort study involving non-anonymous allocation.","authors":"Vivek B Kute, Himanshu V Patel, Subho Banerjee, Divyesh P Engineer, Ruchir B Dave, Nauka Shah, Sanshriti Chauhan, Harishankar Meshram, Priyash Tambi, Akash Shah, Khushboo Saxena, Manish Balwani, Vishal Parmar, Shivam Shah, Ved Prakash, Sudeep Patel, Dev Patel, Sudeep Desai, Jamal Rizvi, Harsh Patel, Beena Parikh, Kamal Kanodia, Shruti Gandhi, Michael A Rees, Alvin E Roth, Pranjal Modi","doi":"10.1111/nep.14380","DOIUrl":"10.1111/nep.14380","url":null,"abstract":"<p><strong>Aim: </strong>In India, 85% of organ donations are from living donors and 15% are from deceased donors. One-third of living donors were rejected because of ABO or HLA incompatibility. Kidney exchange transplantation (KET) is a cost-effective and legal strategy to increase living donor kidney transplantation (LDKT) by 25%-35%.</p><p><strong>Methods: </strong>We report our experience with 539 KET cases and the evolution of a single-centre program to increase the use of LDKT.</p><p><strong>Results: </strong>Between January 2000 and 13 March, 2024, 1382 deceased donor kidney transplantations and 5346 LDKT were performed at our centre, including 10% (n = 539) from KET. Of the 539 KET, 80.9% (n = 436) were ABO incompatible pairs, 11.1% (n = 60) were compatible pairs, and 8% (n = 43) were sensitized pairs. There were 75% 2-way (n = 2 × 202 = 404), 16.2% 3-way (n = 3 × 29 = 87), 3% 4-way (n = 4 × 4 = 16), 1.8% 5-way (n = 5 × 2 = 10), 2.2% 6-way (n = 6 × 2 = 12), and 1.8% 10-way KET (n = 10 × 1 = 10). Of the recipients 81.2% (n = 438) were male and 18.8% (n = 101) were female, while of the donors, 78.5% (n = 423) were female and 21.5% (n = 116) were male. All donors were near relatives; wives (54%, n = 291) and mothers (20%, n = 108) were the most common donors. At a median follow-up of 8.2 years, patient survival, death censored graft survival, acute rejection, and median serum creatinine levels of functioning grafts were 81.63% (n = 440), 91% (n = 494), 9.8% (n = 53) and 1.3 mg/dL respectively. We credited the success to maintaining a registry of incompatible pairs, high-volume LDKT programs, non-anonymous allocation and teamwork.</p><p><strong>Conclusion: </strong>This is the largest single-centre KET program in Asia. We report the challenges and solutions to replicate our success in other KET programs.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"917-929"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NELL-1 membranous nephropathy due to mercury exposure from fairness cream: Report of two cases. 因接触美白霜中的汞而引起的 NELL-1 膜性肾病:两个病例的报告。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-13 DOI: 10.1111/nep.14403
Pankaj Jawandhiya, Ankur Gupta

Mercury contained in beauty-enhancing cosmetics can cause chronic poisoning and membranous nephropathy (MN). We report two cases of nephrotic syndrome caused by MN with evidence of mercury poisoning due to the application of fairness cream in a short duration of a few months. The individuals were positive for neural epidermal growth factor-like 1 [NELL-1]. Discontinuation of the use of cosmetic products and modified Ponticelli regimen improved the nephrotic state in these individuals. We suggest that mercury poisoning should be considered in NELL-1-positive individuals with a history of application of beauty products.

美容化妆品中含有的汞可导致慢性中毒和膜性肾病(MN)。我们报告了两例由 MN 引起的肾病综合征病例,有证据表明他们在短短几个月内使用了美白霜而导致汞中毒。患者的神经表皮生长因子样 1 [NELL-1]呈阳性。停用化妆品和改良的庞蒂切利疗法改善了这些患者的肾病状态。我们建议,对于 NELL-1 阳性且使用过美容产品的患者,应考虑汞中毒。
{"title":"NELL-1 membranous nephropathy due to mercury exposure from fairness cream: Report of two cases.","authors":"Pankaj Jawandhiya, Ankur Gupta","doi":"10.1111/nep.14403","DOIUrl":"10.1111/nep.14403","url":null,"abstract":"<p><p>Mercury contained in beauty-enhancing cosmetics can cause chronic poisoning and membranous nephropathy (MN). We report two cases of nephrotic syndrome caused by MN with evidence of mercury poisoning due to the application of fairness cream in a short duration of a few months. The individuals were positive for neural epidermal growth factor-like 1 [NELL-1]. Discontinuation of the use of cosmetic products and modified Ponticelli regimen improved the nephrotic state in these individuals. We suggest that mercury poisoning should be considered in NELL-1-positive individuals with a history of application of beauty products.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"996-999"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining causes of death-censored kidney allograft failure: A 5-year multicentre ANZDATA and clinical cross-sectional study. 确定肾移植失败的死亡原因:一项为期 5 年的多中心 ANZDATA 和临床横断面研究。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-30 DOI: 10.1111/nep.14397
William R Mulley, Peter D Hughes, Michael G Collins, Helen L Pilmore, Philip A Clayton, Melanie L Wyld, Darren Lee, Jane van der Jeugd, Sanduni C Fernando, Stephanie Fang-Tzu Kuo, Sarah Tan, Sadia Jahan, Wai H Lim

Aim: Determining specific causes of allograft failure allows a focus on understanding and treating these conditions. Previous studies highlight chronic antibody-mediated rejection as a leading cause of late allograft failure. We sought to define causes of allograft failure in a large cohort of kidney transplant recipients across multiple centres in Australia and New Zealand, including cases previously attributed to chronic allograft nephropathy (CAN).

Methods: All death-censored allograft failures at 9 participating centres between 1 January 2014 to 31 December 2018 were included. Available clinical and biopsy data were reviewed and the "most likely" cause assigned.

Results: There were 642 death-censored allograft failures in the study period. Of these, 495 (77.1%) had an informative biopsy performed a median of 13.4 months (IQR 2.5-39.1 months) prior to allograft failure. Rejection of any type was the leading cause of allograft failure (47.5%), comprised chiefly of chronic antibody-mediated rejection (37.4%) and chronic T-cell mediated rejection (6.4%). Other leading causes were undifferentiated interstitial fibrosis and tubular atrophy (10.8%), late medical and surgical complications (8.1%) and recurrent or de novo glomerulonephritis (7.0%). Polyoma viral nephropathy and calcineurin inhibitor toxicity each contributed to <2%. Causes of allograft failure previously attributed to CAN (n = 419, 65.3%) had a similar distribution to the overall cohort, with 43.9% attributed to chronic antibody-mediated rejection.

Conclusion: To prolong allograft survival, improved strategies are needed to curtail alloimmune responses. Greater understanding of the causes of undifferentiated interstitial fibrosis and tubular atrophy and potential treatments would also be of considerable benefit.

目的:确定导致同种异体移植失败的具体原因,有助于了解和治疗这些病症。以往的研究强调,慢性抗体介导的排斥反应是晚期异体移植失败的主要原因。我们试图在澳大利亚和新西兰多个中心的一大批肾移植受者中确定异体移植失败的原因,包括以前归因于慢性异体移植肾病(CAN)的病例:方法:纳入2014年1月1日至2018年12月31日期间9个参与中心的所有死亡删减异体移植失败病例。对现有临床和活检数据进行审查,并确定 "最有可能 "的原因:结果:在研究期间,有642例经死亡筛查的同种异体移植失败。其中,495例(77.1%)在同种异体移植失败前13.4个月(IQR为2.5-39.1个月)进行了知情活检。任何类型的排斥反应都是导致同种异体移植失败的主要原因(47.5%),主要包括慢性抗体介导的排斥反应(37.4%)和慢性T细胞介导的排斥反应(6.4%)。其他主要原因包括未分化间质纤维化和肾小管萎缩(10.8%)、晚期内外科并发症(8.1%)以及复发性或新生肾小球肾炎(7.0%)。多瘤病毒肾病和降钙素蛋白抑制剂的毒性都是造成这一结果的原因:为了延长异体移植的存活时间,需要改进策略来抑制同种免疫反应。进一步了解未分化间质纤维化和肾小管萎缩的原因以及潜在的治疗方法也将大有裨益。
{"title":"Defining causes of death-censored kidney allograft failure: A 5-year multicentre ANZDATA and clinical cross-sectional study.","authors":"William R Mulley, Peter D Hughes, Michael G Collins, Helen L Pilmore, Philip A Clayton, Melanie L Wyld, Darren Lee, Jane van der Jeugd, Sanduni C Fernando, Stephanie Fang-Tzu Kuo, Sarah Tan, Sadia Jahan, Wai H Lim","doi":"10.1111/nep.14397","DOIUrl":"10.1111/nep.14397","url":null,"abstract":"<p><strong>Aim: </strong>Determining specific causes of allograft failure allows a focus on understanding and treating these conditions. Previous studies highlight chronic antibody-mediated rejection as a leading cause of late allograft failure. We sought to define causes of allograft failure in a large cohort of kidney transplant recipients across multiple centres in Australia and New Zealand, including cases previously attributed to chronic allograft nephropathy (CAN).</p><p><strong>Methods: </strong>All death-censored allograft failures at 9 participating centres between 1 January 2014 to 31 December 2018 were included. Available clinical and biopsy data were reviewed and the \"most likely\" cause assigned.</p><p><strong>Results: </strong>There were 642 death-censored allograft failures in the study period. Of these, 495 (77.1%) had an informative biopsy performed a median of 13.4 months (IQR 2.5-39.1 months) prior to allograft failure. Rejection of any type was the leading cause of allograft failure (47.5%), comprised chiefly of chronic antibody-mediated rejection (37.4%) and chronic T-cell mediated rejection (6.4%). Other leading causes were undifferentiated interstitial fibrosis and tubular atrophy (10.8%), late medical and surgical complications (8.1%) and recurrent or de novo glomerulonephritis (7.0%). Polyoma viral nephropathy and calcineurin inhibitor toxicity each contributed to <2%. Causes of allograft failure previously attributed to CAN (n = 419, 65.3%) had a similar distribution to the overall cohort, with 43.9% attributed to chronic antibody-mediated rejection.</p><p><strong>Conclusion: </strong>To prolong allograft survival, improved strategies are needed to curtail alloimmune responses. Greater understanding of the causes of undifferentiated interstitial fibrosis and tubular atrophy and potential treatments would also be of considerable benefit.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"930-940"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome. 第一位被诊断出患有脂蛋白肾小球病和阿尔波特综合征的患者。
IF 2.4 4区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-27 DOI: 10.1111/nep.14399
Lianlian Yang, Guang Yang, Hui Guo

Alport syndrome (AS) is one of the most common inherited kidney disorders, involving pathogenic variants of COL4A3, COL4A4 and COL4A5 genes that lead to disruption of the normal structure of collagen IV protein through improper chain or heterotrimer folding or degradation of heterotrimer components. Lipoprotein glomerulopathy (LPG) is an autosomal dominant disease involving APOE gene mutations disturbing lipoprotein metabolism. We report the first case with both AS and LPG in an 11-year-old girl. The patient presented with blepharedema, and decreased vision. Laboratory examinations showed hematemesis, proteinuria, hypoproteinemia, hyperlipidemia and progressive renal failure. Renal biopsy showed the changes of LPG and AS. Whole-exome sequencing (WES) identified two pathogenic variants, c.127C > T in exon 3 of APOE gene, and c.930 + 1G > A in exon 15 of COL4A4 gene. We emphasize the importance of early completion of renal biopsy and WES for early diagnosis of LPG and AS.

阿尔波特综合征(AS)是最常见的遗传性肾脏疾病之一,涉及 COL4A3、COL4A4 和 COL4A5 基因的致病变异,这些变异会导致胶原蛋白 IV 蛋白的正常结构受到破坏,表现为不正常的链或异三聚体折叠或异三聚体成分降解。脂蛋白肾小球病(LPG)是一种常染色体显性遗传病,涉及干扰脂蛋白代谢的 APOE 基因突变。我们报告了第一例同时患有 AS 和 LPG 的 11 岁女孩。患者出现眼睑水肿和视力下降。实验室检查显示吐血、蛋白尿、低蛋白血症、高脂血症和进行性肾功能衰竭。肾活检显示 LPG 和 AS 的变化。全外显子组测序(WES)发现了两个致病变体,即 APOE 基因第 3 外显子中的 c.127C > T 和 COL4A4 基因第 15 外显子中的 c.930 + 1G > A。我们强调尽早完成肾活检和 WES 对早期诊断 LPG 和 AS 的重要性。
{"title":"First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome.","authors":"Lianlian Yang, Guang Yang, Hui Guo","doi":"10.1111/nep.14399","DOIUrl":"10.1111/nep.14399","url":null,"abstract":"<p><p>Alport syndrome (AS) is one of the most common inherited kidney disorders, involving pathogenic variants of COL4A3, COL4A4 and COL4A5 genes that lead to disruption of the normal structure of collagen IV protein through improper chain or heterotrimer folding or degradation of heterotrimer components. Lipoprotein glomerulopathy (LPG) is an autosomal dominant disease involving APOE gene mutations disturbing lipoprotein metabolism. We report the first case with both AS and LPG in an 11-year-old girl. The patient presented with blepharedema, and decreased vision. Laboratory examinations showed hematemesis, proteinuria, hypoproteinemia, hyperlipidemia and progressive renal failure. Renal biopsy showed the changes of LPG and AS. Whole-exome sequencing (WES) identified two pathogenic variants, c.127C > T in exon 3 of APOE gene, and c.930 + 1G > A in exon 15 of COL4A4 gene. We emphasize the importance of early completion of renal biopsy and WES for early diagnosis of LPG and AS.</p>","PeriodicalId":19264,"journal":{"name":"Nephrology","volume":" ","pages":"985-989"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1